Lefkofsky is certainly a smart businessman with billions in wealth to prove it. Now, he has a biotech startup, Tempus, leading the way with better treatment for cancer patients and a more personalized approach. This startup is taking the Big Data techniques used in marketing and finance to give doctors a better understanding of cancer in each individual patient. The result is something much more effective than the traditionally “one size fits all” approach often used. By giving people customized solutions, doctors will be able to give cancer patients a much better outcome in the end. That’s exactly what Eric Lefkofsky has planned with this company.
Tempus begins its analysis by looking at the genetics and lifestyle of every patient. Everyone is different and there needs to be an approach to treating cancer that reflects this. Tempus has succeeded by giving people who previously haven’t had their specific cancer case closely examined the insight needed to provide good treatment. Essentially, it takes the work doctors normally have to do themselves and automates the process. That gives doctors the ability to spend more time on things that matter to the patient instead of trying to solve everyone with one single solution.
Eric Lefkofsky has already done so much in his life to help out those in need. His Lefkofsky Foundation has given funding to some of the most important causes around the world, but that isn’t enough for him. His desire to change the world around him is never ending and Tempus is only the latest example of that. Cancer isn’t an easy thing to treat or research. The use of tools well beyond human ability is necessary in order to improve the quality of care patients receive. This more personalized approach is becoming the norm in just about everything, so it only makes sense to apply it to this as well. The treatment of complex and serious diseases is going to be one of the most important points of interest for medicine in our age, but the exact way that happens is going to happen on a case by case basis.